942 Hits
942 Hits
1211 Hits
1211 Hits
1523 Hits
1523 Hits
1216 Hits
1216 Hits
1408 Hits
1408 Hits
1972 Hits
1972 Hits
2237 Hits
2237 Hits
1908 Hits
1908 Hits
1545 Hits
1545 Hits
2197 Hits
2197 Hits
2668 Hits
2668 Hits
2248 Hits
2248 Hits
As of January 2021, parties will no longer have free choice on whether a hearing (oral proceedings) during examination or opposition is in person or via video conferencing before the European Patent Office (EPO). Video conferences will be the default. 12 months ago, we would have had to fight for a hearing (oral proceedings) to be held with t...
2336 Hits
2336 Hits
A Supplementary Protection Certificate (SPC) can provide up to five years additional protection for a patented active ingredient of a pharmaceutical product that has received a marketing authorisation. The objective is to compensate a patent holder for the delay in being able to use the patent by the need to obtain the marketing authorisation. An S...
1506 Hits
1506 Hits
We have previously written about our involvement in filing and prosecuting patent applications for two inventions created by the AI inventor DABUS, and naming DABUS (the true deviser of the inventions) as the inventor.The UK IPO found the inventions to be both novel and inventive, and therefore, in principle, protectable by patent. ...
1703 Hits
1703 Hits
Ever since the Decision issued back in 1997 in the case of Biogen v Medeva the concept of insufficiency has been extended, particularly in the chemical and biotech fields, to include claims that have "excessive breadth" (so-called "Biogen insufficiency"). The Courts in the UK have applied this frequently to revoke patents that they decide clai...
2251 Hits
2251 Hits
Regeneron Pharmaceuticals' European patent EP 1360287 and its divisional EP 2264163 relate to methods of producing transgenic mice able to produce antibodies having human sequences, and the mice produced thereby. These patents covered the idea of producing mice having mixed human-murine gene sequences that could be subsequently modified t...
2380 Hits
2380 Hits
2612 Hits
2612 Hits
©
2007 - 2022
Williams Powell
All rights reserved.
Williams Powell are regulated by IPREG whose code of conduct can be found here.These pages aim to provide a source of information for both non-professional enquirers e.g. inventors and their companies in the U.K. and professional consultants and advisers throughout the rest of the world. The pages are not intended to provide legal advice, which will only be provided on direct application to us in the formal context of a client/attorney relationship.
The information provided is correct to the best of our knowledge and belief, but is provided without obligation or guarantee. It will be updated from time to time as needed.